Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 3:11 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 485 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Human Volunteers Clear all

Conditions: Influenza
Interventions: IN Placebo, IM Placebo, BPL-1357; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Volunteers
Interventions: PF-04427429; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Healthy, Lung Disease, Sepsis, Septic Shock
Interventions: Reference Endotoxin, Inhaled Nitric Oxide; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Anthrax
Interventions: AVP-21D9, Placebo; Drug
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Cytomegalovirus Infections
Interventions: TCN-202, Placebo; Biological
Lead sponsor: Theraclone Sciences, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Pain
Interventions: Green Light Emitting Diode, White Light Emitting Diode; Device
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Acquired Immunodeficiency Syndrome, Healthy Volunteers, HIV/AIDS, HIV Diarrhea, Human Immunodeficiency Virus
Interventions: Crofelemer delayed-release tablets 125mg; Drug
Lead sponsor: Napo Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: Tustin, California • Stratford, Connecticut • Springfield, Massachusetts

Conditions: Chronic Hepatitis b
Interventions: ATI-2173 50 mg; Drug
Lead sponsor: Antios Therapeutics, Inc; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy Volunteers
Interventions: CC-90001, Placebo; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Mucosal Immune Response to Influenza Vaccination
Interventions: FluMist (Live Attenuated Influenza Vaccine); Biological
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Healthy Volunteers
Interventions: Gadobutrol; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Placebo Analgesia
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 167 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Hepatitis B
Interventions: ABI-H2158, Placebo for ABI-H2158; Drug
Lead sponsor: Assembly Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: Coronado, California • San Diego, California • San Francisco, California + 1 more

Conditions: Healthy Volunteers
Interventions: TS-161, TS-161 Placebo; Drug
Lead sponsor: Taisho Pharmaceutical R&D Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 25 Years to 35 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Obesity, Healthy Volunteers, Overweight
Interventions: [c11] raclopride, [18F]fallypride; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Participants Study
Interventions: PRX019, Placebo; Drug
Lead sponsor: Prothena Biosciences Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Los Alamitos, California

Conditions: Influenza
Interventions: Licensed seasonal influenza vaccine; Biological
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Human Gastrointestinal Physiology Data
Interventions: Single dose of ibuprofen (800 mg tablet), Pulmocare, two 8.0 oz (236.6 mL) cans; Drug · Dietary Supplement
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Healthy Volunteers
Interventions: GFB-887, Placebo; Drug
Lead sponsor: Goldfinch Bio, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Systemic Lupus Erythematosus
Interventions: AMG 570, AMG 570 Matching Placebo; Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Evansville, Indiana • Overland Park, Kansas • Madison, Wisconsin

Conditions: Healthy Participants
Interventions: AZD5462, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Exocrine Pancreatic Insufficiency, Chronic Pancreatitis
Interventions: Secretin (human synthetic) - ChiRhoClin; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy Volunteers
Interventions: Cold exposure, Normal temperature, Fixed diet, Ad libitum diet, Fasting; Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Phoenix, Arizona

Search by objective public record fields.

Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine

First In Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429 Administered Intravenously To Healthy Adult Volunteers

Effects of Endotoxin in Normal Human Volunteers

Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)

Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody

Green Light Exposure in Healthy Volunteers Exposure in Normal Human Volunteers

Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea

Ethnobridging Study in Healthy Volunteers, Chinese and Japanese Subjects

First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001

How Healthy Adults Respond to the Nasal Flu Vaccine

Dynamic Magnetic Resonance Imaging of Human Subarachnoid Space Using Intrathecal Gadolinium Contrast

Oxytocin and Arginine Vasopressin in Pain Relief

A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis B

First-in-Human Study With Single and Multiple Doses of TS-161 in Healthy Participants

Exploratory Study of Circadian Relationships Between Social Behavior, Blood Pressure and Metabolomics

Brain Dopamine Function in Human Obesity

Phase 1 Study of PRX019 in Healthy Adult Volunteers

Immune Response Following Seasonal Influenza Vaccination

Modernization of in vivo-in Vitro Oral Bioperformance Prediction and Assessment

FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects

Single Ascending Dose Study of AMG 570 in Healthy Subjects

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers

A Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy Subjects

Food Intake Response to Short-Term Modifications of Metabolism in Humans